Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.

@article{Laine2008LowerGE,
  title={Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.},
  author={L Laine and Sean P. Curtis and Michael Langman and Dennis M. Jensen and Byron L. Cryer and Amarjot Kaur and Christopher P. Cannon},
  journal={Gastroenterology},
  year={2008},
  volume={135 5},
  pages={1517-25}
}
BACKGROUND & AIMS Nonsteroidal anti-inflammatory drugs (NSAIDs) cause lower gastrointestinal (GI) clinical events such as bleeding. Cyclo-oxygenase (COX)-2 selective inhibitors decrease upper GI events, but no prospective trial has prespecified assessment of lower GI clinical events. METHODS Patients >or=50 years old with osteoarthritis or rheumatoid arthritis were randomly assigned to etoricoxib (60 or 90 mg qd) or diclofenac (150 mg qd). Lower GI clinical events, confirmed by a blinded… CONTINUE READING
41 Extracted Citations
26 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 41 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 26 references

Committee meeting

  • FDA Arthritis Advisor
  • February 7, 2001. Available at: http://www.fda…
  • 2008

Similar Papers

Loading similar papers…